A Phase 1b/2 Study of Hu5F9-G4 (Magrolimab) in Combination With Mogamulizumab in Relapsed/Refractory Treated T-Cell Lymphoma
Latest Information Update: 16 Jul 2024
At a glance
- Drugs Magrolimab (Primary) ; Mogamulizumab (Primary)
- Indications Mycosis fungoides; Sezary syndrome; T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 01 Jun 2024 Planned End Date changed from 31 Dec 2025 to 30 Jun 2025.
- 01 Jun 2024 Planned primary completion date changed from 31 Dec 2025 to 30 Jun 2025.
- 09 Feb 2024 Status changed from suspended to active, no longer recruiting.